|
|
|
16 Million
|
The number of people aged 65 and older in the U.S. who live alone. Caring for them has become increasingly difficult for families and organizations.
|
|
|
|
|
|
|
PHOTO: SERGIY BARCHUK FOR WSJ. MAGAZINE
|
|
|
|
Chill pill? The beta blocker propranolol has become the go-to pill for dealing with stressful situations, from public speaking to first dates to weddings. Musicians and actors have long relied on beta blockers–which slow the heart rate and lower blood pressure–before performing. Now a new generation of stars is spreading the gospel.
|
|
Swearing off ultra-processed foods. Amid rising concerns about the health effects, one family tried to stop eating “UPF”s for one month. For them, that meant eliminating all foods with artificial flavors and anything with refined flours, including most crackers and granola bars. Here’s what they learned.
|
|
Are you “tanmaxxing”? After years of skin care obsessives preaching the gospel of sun protection, extreme tanning is back. The UV index, developed to help people take precautions against excessive sun exposure, is now being used by some to identify when tanning will produce the most dramatic effect. Tanning devotees are advocating using little to no sunscreen.
|
|
|
|
|
PHOTO: MICHAEL BUCHER/WSJ
|
|
|
|
Are you “fibermaxxing”? Food companies are packing fiber into everything from soda to doughnuts and snack bars. “Fibermaxxing,” where people post their efforts to load up on fiber, is trending on social media. But emerging research shows that some fibers in these products, especially in high doses, could lead to health problems in some people.
|
|
Wegovy cuts heart risk. Novo Nordisk said its blockbuster weight-loss drug cuts the risk of heart attack, stroke or death by 57% compared with Eli Lilly’s Mounjaro and Zepbound. The real-world study used evidence gathered from actual patient experiences rather than a controlled trial, the Danish company said.
|
|
|
This newsletter was compiled by the WSJ’s Health & Science team. Follow us on X @WSJHealth and @WSJScience. Email us by replying to this newsletter.
|
|
|
|
|